NDAORALSUSPENSIONPriority Review
Approved
Apr 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
ELIQUIS (apixaban) by Bristol Myers Squibb is fxa. Approved for atrial fibrillation, deep vein thrombosis, pulmonary embolism and 1 more indications. First approved in 2025.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELIQUIS (apixaban) is an oral Factor Xa inhibitor anticoagulant that prevents blood clots by inhibiting free and clot-bound FXa without requiring antithrombin III cofactor. It is approved for stroke prevention in atrial fibrillation, venous thromboembolism treatment and prophylaxis, and emerging indications including cancer-associated thrombosis and antiphospholipid syndrome. The drug works by decreasing thrombin generation and thrombus development through selective FXa inhibition.
$18.3BPart D
PeakStable
15.0 years to LOEELIQUIS remains the market-leading anticoagulant with substantial revenue, supporting large commercial and medical affairs teams despite competitive pressure from other Factor Xa inhibitors.
Mechanism of Action
FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban…
Indications (4)
Worked on ELIQUIS at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.